|Free Dividend Report|
|Stock Splits Calendar|
|NAVB Stock Split History|
|Preferred Stock Newsletter|
|NAVB Options Chain|
|Stock Message Boards|
Navidea Biopharmaceuticals (NAVB) has 1 split in our NAVB split history database. The split for NAVB took place on April 26, 2019. This was a 1 for 20 reverse split, meaning for each 20 shares of NAVB owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 50 share position following the split.
When a company such as Navidea Biopharmaceuticals conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the NAVB split history from start to finish, an original position size of 1000 shares would have turned into 50 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Navidea Biopharmaceuticals shares, starting with a $10,000 purchase of NAVB, presented on a split-history-adjusted basis factoring in the complete NAVB split history.
Growth of $10,000.00
Without Dividends Reinvested
|Average Annual Total Return:||-41.75%|
|About Navidea Biopharmaceuticals|
|Navidea Biopharmaceuticals is a biopharmaceutical company focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. Co. is developing multiple precision-targeted products based on its Manocept platform to improve patient care by identifying the sites and pathways of undetected disease and enable diagnostic, clinical decision-making and targeted treatment. Co.'s business is focused on two primary types of drug products: diagnostic substances, including Tc99m tilmanocept and other diagnostic applications of its Manocept platform; and therapeutic development programs, including therapeutic applications of its Manocept platform. According to our NAVB split history records, Navidea Biopharmaceuticals has had 1 split.|
|NAVB Split History Table|
|04/26/2019||1 for 20|
|Healthcare Stock Splits|
|NAVB is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:|